Bafna Pharmaceuticals Limited (BAFNAPH) AI Stock Analysis

• Market Cap: ₹2.68B
• Dividend Yield: N/A
• Average Volume (3M): 1.19K
• Price to Earnings (P/E): 48.5
• Beta (1Y): 0.27
• Revenue Growth: -0.77%
• EPS Growth: 2055.99%
• Country: IN
• Employees: 363
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.78
• Shares Outstanding: 23,656,336
• 10 Day Avg. Volume: 1,123
• 30 Day Avg. Volume: 1,187
• PEG Ratio: -0.98
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 1.22
• P/FCF Ratio: -76.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ₹130.00 ▼(-15.94% Downside)
• Action: Reiterated Date: 01/21/26
• Date: Action: Reiterated 01/21/26

The score is driven primarily by solid historical revenue growth and a generally stable balance sheet, but it is held back by recent profitability and cash flow weakness. Technical indicators are notably bearish (below key moving averages with negative MACD), and valuation looks relatively high at ~31.5x earnings with no dividend yield provided.

Positive Factors

Historical Revenue Growth

Consistent multi-year revenue expansion indicates the company has built distribution, product adoption and market traction, creating a larger, more predictable revenue base. That scale supports reinvestment in R&D and capacity and reduces execution risk over the next several months.

Negative Factors

Volatile Free Cash Flow

Material volatility and a recent negative free cash flow trend weaken self-funding capacity and raise liquidity risk. This instability can constrain capex, delay strategic projects, and increase reliance on debt or equity financing, affecting resilience over the coming months.

Bafna Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceutical...

Read more

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceutical...

How the Company Makes Money

null...

Bafna Pharmaceuticals Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.42B	1.46B	1.52B	1.15B	851.40M	712.18M
Gross Profit	408.55M	168.77M	452.15M	387.56M	338.60M	257.62M
EBITDA	167.13M	117.73M	146.34M	189.88M	112.34M	103.94M
Net Income	87.72M	41.52M	73.48M	113.38M	52.16M	58.27M
Balance Sheet
Total Assets	1.61B	1.53B	1.48B	1.30B	901.45M	864.66M
Cash, Cash Equivalents and Short-Term Investments	19.67M	34.33M	13.96M	78.09M	194.00K	18.04M
Total Debt	324.03M	281.99M	243.89M	229.24M	110.59M	130.00M
Total Liabilities	694.55M	682.73M	668.43M	561.29M	281.81M	296.95M
Stockholders Equity	912.28M	848.07M	808.39M	734.55M	619.64M	567.71M
Cash Flow
Free Cash Flow	-71.04M	-23.31M	-60.93M	-32.66M	21.87M	-197.04M
Operating Cash Flow	93.13M	195.29M	94.85M	49.52M	97.28M	-136.09M
Investing Cash Flow	-149.13M	-213.02M	-150.54M	-74.93M	-65.44M	-53.45M
Financing Cash Flow	24.23M	38.09M	-8.45M	101.77M	-48.15M	122.80M

Bafna Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 154.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Negative. The current price of 154.65 is above the 20-day moving average (MA) of 110.22, above the 50-day MA of 115.78, and above the 200-day MA of 124.16, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 49.42 is Neutral, neither overbought nor oversold. The STOCH value of 61.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAFNAPH.

Bafna Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	60 Neutral	₹1.09B	21.48	―	―	14.53%	-10.49%
BAFNAPH	58 Neutral	₹2.68B	48.53	―	―	-0.77%	2055.99%
BALPHARMA	58 Neutral	₹1.05B	16.40	―	1.62%	-9.07%	5.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MANGALAM	50 Neutral	₹449.68M	-1.11	―	―	-24.55%	-310.57%
AAREYDRUGS	47 Neutral	₹1.58B	84.53	―	―	-17.47%	-50.07%
KREBSBIO	43 Neutral	₹940.69M	-11.90	―	―	-46.31%	-26.28%

Bafna Pharmaceuticals Limited Corporate Events